Track Record

Dec, 14, 2018 Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -

Nov, 22, 2018 Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas

Oct, 23, 2018 Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App

Aug, 10, 2018 Astellas Announces Acquisition of Quethera - Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma -

May, 10, 2018 Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

Feb, 14, 2018 Astellas Acquires Universal Cells, Inc.

Dec, 1, 2017 Astellas Acquires Mitobridge Under Existing Collaboration

Feb, 28, 2017 Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease

Feb, 27, 2017 Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan

Jan, 31, 2017 Astellas Executes License Agreement with Auration Biotech for the Development and Commercialization of AU-935

Dec, 12, 2016 Astellas Announces Transfer of Qutenza to Grünenthal

Oct, 28, 2016 Astellas to Acquire Ganymed Pharmaceuticals -Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage -

Sep, 28, 2016 Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area

Jul, 28, 2016 CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS

Jun, 23, 2016 The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine

May, 25, 2016 Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.

Feb, 01, 2016 Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa

Dec, 11, 2015 Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy

Nov, 20, 2015 Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Nov, 18, 2015 Presentation for Astellas to Acquire Ocata Therapeutics

Nov, 11, 2015 Astellas Transfers Its Global Dermatology Business to LEO Pharma

Oct, 09, 2015 Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease

Sep, 30, 2015 Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

Jun, 02, 2015 Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -

Apr, 22, 2015 Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collaboration Includes Option for Astellas to Acquire Potenza -

Apr, 15, 2015 MSD and Astellas sign a memorandum of understanding regarding co-development and co-commercialization of combination product of JANUVIA® and Suglat®, oral treatments for type 2 diabetes

Apr, 03, 2015 MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

Jan, 30, 2015 Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis

Nov, 04, 2014 DANA-FARBER CANCER INSTITUTE AND ASTELLAS ANNOUNCE - Focus on research and development for small molecule inhibitors of oncogenic K-Ras- the most commonly mutated oncogene in human cancers -

Oct, 14, 2014 ASTELLAS ANNOUNCES RESEARCH COLLABORATION WITH HARVARD MEDICAL SCHOOL INVESTIGATOR FOR TREATMENT OF RETINAL DEGENERATION - AIMing to establish a new treatment for ophthalmologic diseases -

Aug, 08, 2014 CANCER RESEARCH UK AND CANCER RESEARCH TECHNOLOGY JOIN FORCES WITH ASTELLAS ON AUTOPHAGY TO FIND NEW CANCER TREATMENTS

Jan, 06, 2014 ASTELLAS TO FORM STRATEGIC PARTNERSHIP WITH CLEARPATH TO BUILD VACCINE PORTFOLIO　-In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics-

Dec, 25, 2013 Astellas and IBL Concludes Co-Research Agreement Regarding Pharmaceutical Applications of Recombinant Human Proteins Made Using transgenic Silkworms

Oct, 07, 2013 ASTELLAS AND MITOKYNE TO PURSUE MITOCHONDRIA-RELATED DISEASE THERAPIES　- Collaboration Will Focus on Expanding the New Frontier of Mitochondria-related Disease -

Sep, 02, 2013 Astellas and MSD Enter Co-Promotion Agreement in Japan for Ipragliflozin, SGLT2 Inhibitor for Treatment of Type 2 Diabetes

Jun, 28, 2013 Seattle Genetics and Agensys, an affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration

Jun, 26, 2013 CYTOKINETICS AND ASTELLAS ANNOUNCE COLLABORATION IN THE FIELD OF SKELETAL MUSCLE ACTIVATION

May, 07, 2013 Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion

Apr, 05, 2013 Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

Oct, 02, 2012 Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas' Oral JAK Inhibitor for Immunologic Diseases

Jun, 04, 2012 Astellas and Drais Partner To Develop Second Astellas Compound through Seldar

Apr, 25, 2012 Astellas and Drais Partner To Develop Astellas Compound through Telsar

Mar, 30, 2012 Optimer Pharmaceuticals, Inc. and Astellas Pharma Inc. Enter Collaboration to Commercialize Fidaxomicin for Clostridium difficile Infection in Japan

Feb, 01, 2012 UCB and Astellas announce agreement to jointly develop and commercialize Cimzia® (certolizumab pegol) in Japan

Dec, 21, 2011 AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion

Nov, 08, 2011 Collaborative Research Launched to Explore Novel Drug Targets for Alzheimer's Disease RIKEN Brain Science Institute and Astellas Pharma Form Strategic Alliance for New Drug Discovery

Sep, 05, 2011 Astellas Pharma signs a license agreement with Evec for a fully-human antibody

Jul, 27, 2011 Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico andthe United States from Astellas (pdf 30KB)

Jul, 15, 2011 Vical and Astellas Announce Worldwide License Agreements for TransVax™ Cytomegalovirus Vaccine

Jun, 30, 2011 Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million

May, 17, 2011 Astellas and Maxygen Announce Completion of Acquisition of Perseid by Astellas

May, 17, 2011 Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

Dec, 08, 2010 Astellas Pharma Enters Strategic Equity Deal with Cytori ; To Purchase $10 Million in Equity at $7.00 per Share

Nov, 01, 2010 Astellas Pharma Inc.: Enter into Option Agreement with Alavita to Acquire Diannexin Assets

Oct, 19, 2010 Astellas and ASKA Enter into License Agreement for AKP-002

Sep, 30, 2010 Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan

Jul, 28, 2010 Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023

May, 17, 2010 Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.

Feb, 24, 2010 Entered into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole

Dec, 18, 2009 Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications

Nov, 24, 2009 Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration

Nov, 10, 2009 Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide

Oct, 28, 2009 Astellas and Medivation Enter into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer

Aug, 03, 2009 Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved SumavelTM DoseProTM -- Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache --

Jul, 01, 2009 Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals

Jun, 23, 2009 NeurogesX and Astellas Enter Commercialization Agreement for Qutenza TM